Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has reported promising results from a Phase IIb trial of eftilagimod alfa (efti) in combination with KEYTRUDA in treating patients with negative PD-L1 expression in head and neck cancers, achieving a 35.5% response rate and significant complete responses. Over half of the patients were treated for at least six months, showing good treatment durability and safety. These results may offer a new immunotherapy option for patients and will lead to discussions with regulatory agencies.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
